Request Trial
19 April 2013Pharma

OFT accuses GSK of market abuse over pay-for-delay deals

The UK Office of Fair Trading (OFT) has accused pharmaceutical firm GlaxoSmithKline (GSK) of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
22 October 2026   Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.
Pharma
Amarin and Hikma call time on six-year skinny label fight
22 October 2026   Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026   In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

10x and Parse set to end sequencing feud after appeals court defeat
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
Amarin and Hikma call time on six-year skinny label fight
WATCH: Medmix global IP head on building business-focused IP teams
Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise
Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
Align Technology notches another win in escalating clear aligner feud